Pfizer Inc. is in talks to acquire biotech Seagen Inc., according to people familiar with the matter, the latest potential deal for a big drug company aimed...
Pfizer Inc. PFE is in talks to acquire biotech Seagen Inc. SGEN, according to people familiar with the matter, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies.
The talks are at an early stage and there is no guarantee there will be a deal, the people said. A number of hurdles would need to be overcome, including the potential for a stringent antitrust review of any proposal. If there is a deal, it would be big: Seagen has a market value of some $30 billion and would be expected to command a premium over that.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
WSJ News Exclusive | Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 BillionBreaking: Pfizer is in early-stage talks to acquire biotech Seagen, valued at about $30 billion, and its pioneering targeted cancer therapies
Lire la suite »
Save $30 on the PlayStation 5 bundled with God of War RagnarökThe PlayStation 5 bundle with God of War Ragnarök is $30 off at Woot
Lire la suite »
Merck's Big Upgrade: 4 Big Analyst Calls | Pro Recap | Investing.comStocks Analysis by Garrett Cook covering: Alcoa Corp, Merck & Company Inc, Wingstop Inc, Dun And Bradstreet Holding Inc. Read Garrett Cook's latest article on Investing.com
Lire la suite »
FDA Flags ‘Important Potential Risk’ in Pfizer’s RSV VaccineTwo adults in their 60s were diagnosed with Guillain-Barre syndrome after getting the shot in a clinical trial.
Lire la suite »
Pharma companies team up with DeSci to accelerate scientific researchDeSci has fostered the emergence of a thriving ecosystem encompassing projects from decentralized biotech foundations to funding vehicles.
Lire la suite »
Jazz Pharma ruling clears U.S. roadblock for rival narcolepsy drugA U.S. appeals court ordered Jazz Pharmaceuticals Inc (JAZZP.UL) on Friday to de-list a patent related to its blockbuster narcolepsy drug Xyrem from the U.S. Food and Drug Administration's register of approved medications, in a win for rival drugmaker Avadel CNS Pharmaceuticals Inc.
Lire la suite »